RecruitingNCT07107919

Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective

Sponsor

The Affiliated Hospital of Qingdao University

Enrollment

60 participants

Start Date

Jul 30, 2025

Study Type

OBSERVATIONAL

Conditions

Chronic Kidney Disease Cardiac Magnetic Resonance 18F-FAPI

Summary

This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL/min/1.73 m²）,Group II :CKD stages 4-5(eGFR \< 30 mL/min/1.73 m²). Using 18F-FAPI PET/MR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is using advanced imaging — including a special PET/MRI scan with a tracer called 18F-FAPI — to assess how chronic kidney disease (CKD) affects the heart and kidneys together (what doctors call the cardio-renal connection) at different stages of the disease. **You may be eligible if:** - You are between 18 and 80 years old - You have been diagnosed with chronic kidney disease based on established medical guidelines - Your medical records are complete and available - You are willing to undergo the PET/MRI imaging and follow contraception requirements during and after the study **You may NOT be eligible if:** - You are pregnant, planning to become pregnant, or breastfeeding - You have conditions that make the PET/MRI scan unsafe - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHER18F PET/MR

Tracer: \^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq/kg is administered. • Simultaneous PET/MR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds. 1. Cardiac Morphology and Function (Localization \& Cine):Assess cardiac structure and global/regional function 2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema 3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects 4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis 5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis 6. T2 Mapping (Pre Contrast):Quantify myocardial edema 7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \^18F FAPI PET data